Located in Hong Kong Science Park, CDD was established with funding from the InnoHK Initiative of the Hong Kong SAR Government’s Innovation and Technology Commission
The Hong Kong Baptist University (HKBU) established the Center for Chinese Herbal Medicine Drug Development (CDD), which is equipped with comprehensive and state-of-the-art facilities that can improve Hong Kong’s ability to develop new Chinese medicine drugs ( CM) according to market demands. . It will also standardize and internationalize the development of CM drugs and develop talent for the industry.
Along with the opportunities arising from the commissioning of Hong Kong’s first Chinese medicine hospital, the establishment of this unique CM drug development platform will hopefully accelerate the development of innovative CM drugs in Hong Kong.
The Center is currently working on two new CM drug research projects that focus on chronic constipation and inflammatory bowel disease, respectively.
The Center has established six research platforms, including the Clinical Data Science Group, the Gut Microbiota and Metabolism Group, the Gut Inflammation Group, the Chinese Medicine Pharmacognosy Group, the AI-driven Drug Discovery Group, and the Drug Application Group.
Image caption – Left to right: Professor Lyu Aiping, Dean of Chinese Medicine; Professor Guo Yike, Vice-President (Research and Development); Professor Alexander Wai, President and Vice-Chancellor; Professor Rick Wong, Acting President; and Professor Bian Zhaoxiang, Associate Vice President (Chinese Medicine Development) and Clinical Division Director of the HKBU School of Chinese Medicine, who is also the Director of CDD.